Risk of Earnings Pressure from Revisions to the National Health Insurance Drug Price Standard and Dispensing Fees
First written in FY2016. 14 of 20 entries say "Materialised", first in FY2017-Q1. Latest entry: 2026-11-10.
Medical System Network moved to the "Worse" side of this theme in 2016, 10 years before the typical company in this theme (2026).
The whole theme swung hardest in 2026: 4 of 7 companies on the "Worse" side.
1 other company's latest entry also says "Restated".
- 2026-11-10RestatedEarnings presentation materials
「薬価改定及び調剤報酬改定の影響に加え、一過性のシステム投資が増加」
通期業績予想において、薬価・調剤報酬改定の影響が引き続き業績変動要因として記載された。 - FY2024-Q2MaterialisedAnnual report
「Although prescription unit prices declined in the community pharmacy business due to the expiration of transitional measures for the community support system add-on, among other factors,」
The effects of the expiration of transitional measures for the community support system add-on, among other factors, actually emerged as lower prescription unit prices. - FY2024-Q1MaterialisedAnnual report
「Although prescription unit prices declined in the community pharmacy business due to the effects of interim-year drug price revisions and the expiration of transitional measures for the community support system add-on, among other factors,」
The effects of interim-year drug price revisions and the expiration of transitional measures for the community support system add-on, among other factors, actually emerged this quarter as lower prescription unit prices. - FY2023-Q3MaterialisedAnnual report
「During the first 3 quarters of the current consolidated cumulative period, in the community pharmacy division, prescription prices declined due to the impact of the April 2022 revisions to drug prices and dispensing fees. However, stores acquired through new openings and M&A contributed to performance, and new memberships in the pharmaceutical network division remained steady. As a result, net sales were ¥81,878 million, up 2.5% year on year. On the profit side, due to the implementation of the revisions to drug prices and dispensing fees in the community pharmacy division and higher labour costs associated with strengthening face-to-face services, operating profit was ¥2,344 million, down 23.5%; ordinary profit was ¥2,499 million, down 28.3%; and quarterly profit attributable to owners of the parent was ¥1,195 million, down 44.3%.」
The effects of the April 2022 revisions to drug prices and dispensing fees have actually emerged in the third quarter as lower prescription unit prices and declines in profit at each stage. - FY2023-Q2MaterialisedAnnual report
「In the regional pharmacy segment, prescription revenue per prescription declined due to the impact of revisions to drug prices and dispensing fees, but the number of prescriptions filled increased, partly because of contributions from newly opened stores and stores acquired through M&A.」
The effects of the April 2022 revisions to drug prices and dispensing fees have actually emerged this quarter as lower prescription unit prices. - FY2023-Q1MaterialisedAnnual report
「During the first quarter of the current consolidated cumulative period, in the community pharmacy division, prescription prices declined due to the impact of the April 2022 revisions to drug prices and dispensing fees. However, stores acquired through new openings and M&A contributed to performance, and new memberships in the pharmaceutical network division remained steady. As a result, net sales were ¥26,299 million, up 1.5% year on year. On the profit side, due to the implementation of the revisions to drug prices and dispensing fees in the community pharmacy division and higher labour costs associated with strengthening face-to-face services, operating profit was ¥348 million, down 47.7%; ordinary profit was ¥392 million, down 58.1%; and quarterly profit attributable to owners of the parent was ¥91 million, down 84.4%.」
The effects of the April 2022 revisions to drug prices and dispensing fees have actually emerged as lower prescription unit prices and declines in operating profit, ordinary profit and quarterly net income attributable to owners of the parent. - FY2022RestatedAnnual report
「Accordingly, revisions to drug prices and dispensing fees may affect the performance of community pharmacies.」
Continues to describe the risk that revisions to drug prices and dispensing fees will affect the performance of community pharmacies. - FY2022-Q3RestatedAnnual report
「In the pharmaceutical network business, the environment surrounding the pharmacy industry is becoming increasingly challenging, including the launch of interim-year drug price revisions in April 2021.」
Continues to describe the challenging earnings environment for the pharmacy industry, including the launch of interim-year drug price revisions. - FY2022-Q2RestatedAnnual report
「In the pharmaceutical network business, the environment surrounding the pharmacy industry is becoming increasingly challenging, including the launch of interim-year drug price revisions in April 2021.」
Continues to describe the interim-year drug price revision launched in April 2021 and the increasingly challenging earnings environment for the pharmacy industry. - FY2022-Q1WorsenedAnnual report
「In the pharmaceutical network business, the environment surrounding the pharmacy industry is becoming increasingly challenging, including the launch of interim-year drug price revisions in April 2021.」
States that the launch of the April 2021 interim-year drug price revision made the earnings environment surrounding the pharmacy industry increasingly challenging. - FY2021MaterialisedAnnual report
「Revisions to official drug prices and dispensing fees were implemented in April 2020, including reductions in official drug prices and revisions to basic dispensing fees.」
The April 2020 revision of drug prices and dispensing fees was implemented, resulting in actual regulatory changes affecting the earnings environment for the dispensing pharmacy business. - FY2019MaterialisedAnnual report
「On the profit side, due to the impact of the April 2018 revisions to drug prices and dispensing fees, among other factors, operating profit was ¥1,428 million, down 54.8%; ordinary profit was ¥1,501 million, down 53.8%; and profit attributable to owners of the parent was ¥462 million, down 54.7%.」
The impact of the April 2018 revisions to official drug prices and dispensing fees materialized over the full fiscal year as substantial declines in operating profit, ordinary profit and net income attributable to owners of the parent. - FY2019-Q3MaterialisedAnnual report
「In terms of profit, operating profit was ¥1,040 million, down 54.5% year on year, ordinary profit was ¥1,010 million, down 56.7%, and quarterly net income attributable to owners of the parent was ¥372 million, down 60.6%, due to the impact of the revisions to official drug prices and dispensing fees implemented in April 2018, among other factors.」
The impact of the April 2018 revisions to official drug prices and dispensing fees continues to materialize as substantial declines in operating profit, ordinary profit and quarterly net income attributable to owners of the parent. - FY2019-Q2MaterialisedAnnual report
「In terms of profit, operating profit was ¥476 million, down 62.5% year on year, ordinary profit was ¥438 million, down 65.5%, and quarterly net income attributable to owners of the parent was ¥119 million, down 67.0%, due to the impact of the revisions to official drug prices and dispensing fees implemented in April 2018, among other factors.」
The impact of the April 2018 revisions to official drug prices and dispensing fees continues to materialize as substantial declines in operating profit, ordinary profit and quarterly net income attributable to owners of the parent. - FY2019-Q1MaterialisedAnnual report
「In terms of profit, operating profit was ¥212 million, down 64.2% year on year, ordinary profit was ¥192 million, down 67.3%, and quarterly net income attributable to owners of the parent was ¥101 million, down 65.1%, due to the impact of the revisions to official drug prices and dispensing fees implemented in April 2018, among other factors.」
The impact of the April 2018 revisions to official drug prices and dispensing fees continues to materialize as substantial declines in operating profit, ordinary profit and quarterly net income attributable to owners of the parent. - FY2017MaterialisedAnnual report
「The Group's performance is showing a recovery trend, with the rate of decline in profit compared with the same period of the previous year narrowing each quarter throughout the fiscal year as it advanced its response to the official drug price and dispensing fee revisions implemented in April 2016, among other factors.」
The impact of the revisions to official drug prices and dispensing fees materialized over the full fiscal year as a 44.1% decline in operating profit and a 32.2% decline in operating profit in the dispensing pharmacy business, while the rate of decline in profit narrowed as the response progressed. - FY2017-Q3MaterialisedAnnual report
「In terms of profit, operating profit was ¥1,469 million, down 37.8% year on year, due to the impact of the April 2016 revisions to official drug prices and dispensing fees, among other factors. The rate of decline in profit compared with the same period of the previous year narrowed from that in the first six months of the fiscal year as the Group advanced its response to the dispensing fee revisions.」
The impact of revisions to official drug prices and dispensing fees also materialized in the third quarter as a 37.8% year-on-year decrease in operating profit. - FY2017-Q2MaterialisedAnnual report
「While appropriately responding to the dispensing fee revisions implemented in April 2016, the Group is promoting home healthcare initiatives and the provision of functions as family pharmacies and pharmacists as a community pharmacy supporting the health of local residents in various ways. During the first six months of the fiscal year, revenue was ¥39,858 million, up 1.6% year on year, despite a decline in prescription fees per prescription, as newly opened stores and stores acquired through M&A contributed to performance, among other factors. In terms of profit, operating profit was ¥706 million, down 49.6% year on year, due to the impact of the April 2016 revisions to official drug prices and dispensing fees, among other factors.」
The impact of revisions to official drug prices and dispensing fees continues to materialize as a decline in prescription fees per prescription and a 49.6% year-on-year decrease in operating profit in the dispensing pharmacy business. - FY2017-Q1MaterialisedAnnual report
「Although prescription fees per prescription declined due to the revisions to official drug prices and dispensing fees, revenue was ¥21,495 million, up 0.9% year on year, because newly opened stores and stores acquired through M&A contributed to performance, among other factors. In terms of profit, operating profit was ¥270 million, down 56.2% year on year, due to the impact of the revisions to official drug prices and dispensing fees, among other factors.」
The previously identified risk from revisions to official drug prices and dispensing fees is stated to have materialized as a decline in prescription fees per prescription and a decrease in operating profit. - FY2016First statedAnnual report
「Revisions to official drug prices and dispensing fees may affect the performance of dispensing pharmacies.」
The April 2016 revisions, including reductions in official drug prices and special provisions for large pharmacy groups, are identified as short-term factors putting pressure on performance.